Rasburicase Biosimilar candidate

Paras Biopharmaceuticals has been intensively working on a Romiplostim biosimilar known as Elitek™ / Fasturtec™) and has progressively achieved success. The company plans to mature good value within its Rasburicase asset and would like to highlight the following points / highlights to gauge your level of interest. Elitek™ / Fasturtec™ (originator – Sanofi) indicated for use in the pediatric population for the management of elevated uric acid in patients who are receiving chemotherapy for leukemia, lymphoma, or solid tumors and are anticipated to develop tumor lysis and elevated uric acid levels Paras Biopharmaceuticals have worked very extensively on Rasburicase and have development, substantial data (unique program) For further development and registration / approval, very limited further expenses are to made and hence the partnership. Furthermore, Paras Biopharmaceuticals seems to be the only company other than the innovator on such program. Paras Biopharmaceuticals looks to mature maximum value to the pool / joint sharing for further growth / return / rewards from the program. If you have an interest in the product and would like to know more, we would welcome the opportunity to set up a onsite meeting.